Checkpoint blockade and microsatellite instability

US11325974B2 · kind B2 · utility

Assignee

• THE JOHNS HOPKINS UNIVERSITY · US

Inventors

• Luis Diaz · Ellicott City, US
• Bert Vogelstein · Baltimore, US
• Kenneth W. Kinzler · Baltimore, US
• Nickolas Papadopoulos · Towson, US
• Dung Le · Timonium, US
• Drew M. Pardoll · Silver Spring, US
• Suzanne L. Topalian · Silver Spring, US

Key dates

• Filing date: Dec 22, 2020
• Grant date: May 10, 2022
• Expiry date: Dec 22, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q2600/156
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Blockade of immune checkpoints such as cytotoxic T-lymphocyte antigen-4 (CTLA-4) and programmed death-1 (PD-1) shows promise in patients with cancer. Inhibitory antibodies directed at these receptors have been shown to break immune tolerance and promote anti-tumor immunity. These agents work particularly well in patients with a certain category of tumor. Such tumors may be particularly susceptible to treatment because of the multitude of neoantigens which they produce.